Brief PANSS to assess and monitor the overall severity of schizophrenia

Yamamoto, Nobutomo; Inada, Toshiya; Shimodera, Shinji; Morokuma, Ippei; Furukawa, Toshi A

doi:10.1111/j.1440-1819.2010.02081.x

Cited by 9 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary outcomes included total scores on the Client Satisfaction Questionnaire (CSQ-8) [ 27 ], collected at first follow-up, and the Drug Attitude Inventory 10 (DAI-10) [ 28 ], the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS) [ 29 ] and the Brief Positive and Negative Syndrome Scale (Brief PANSS) , all collected at second follow-up. The Brief PANSS was developed by Yamamoto et al 2010 and correlates highly with the full PANSS [ 30 ]. We added an item on hallucinations, since this is not included, and it was anticipated to be a common symptom among our sample.…”

Section: Methodsmentioning

confidence: 99%

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

et al. 2016

View full text Add to dashboard Cite

BackgroundGovernment policy encourages increasing involvement of patients in their long-term care. This paper describes the development and pilot evaluation of a ‘Medication Review Tool’ designed to assist people to participate more effectively in discussions about antipsychotic drug treatment.MethodsThe Medication Review Tool developed consisted of a form to help patients identify pros and cons of their current antipsychotic treatment and any desired changes. It was associated with a website containing information and links about antipsychotics. For the trial, participants diagnosed with psychotic disorders were recruited from community mental health services. Cluster randomisation was used to allocate health professionals (care co-ordinators) and their associated patients to use of the Medication Review Tool or usual care. All participants had a medical consultation scheduled, and those in the intervention group completed the Medication Review Tool, with the help of their health professional prior to this, and took the completed Form into the consultation. Two follow-up interviews were conducted up to three months after the consultation. The principal outcome was the Decision Self Efficacy Scale (DSES). Qualitative feedback was collected from patients in the intervention group.ResultsOne hundred and thirty patients were screened, sixty patients were randomised, 51 completed the first follow-up assessment and 49 completed the second. Many patients were not randomised due to the timing of their consultation, and involvement of health professionals was inconsistent. There was no difference between the groups on the DSES (-4.16 95 % CI -9.81, 1.49), symptoms, side effects, antipsychotic doses or patient satisfaction. Scores on the Medication Adherence Questionnaire indicated an increase in participants’ reported inclination to adherence in the intervention group (coefficient adjusted for baseline values -0.44; 95 % CI -0.76, -0.11), and there was a small increase in positive attitudes to antipsychotic medication (Drug Attitude Inventory, adjusted coefficient 1.65; 95 % CI -0.09, 3.40). Qualitative feedback indicated patients valued the Tool for identifying both positive and negative aspects of drug treatment.ConclusionsThe trial demonstrated the design was feasible, although challenges included service re-configurations and maintaining health professional involvement. Results may indicate a more intensive and sustained intervention is required to facilitate participation in decision-making for this group of patients.Trial registrationCurrent controlled trials ISRCTN12055530, Retrospectively registered 9/12/2013.

show abstract

Section: Methodsmentioning

confidence: 99%

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recently, Yamamoto et al . demonstrated that CGI‐Change (CGI‐C; same as CGI‐I) scores were significantly and positively associated with changes in positive syndrome scale scores, negative syndrome scale scores, and general pathological syndrome scale scores 5 …”

Section: Methodsmentioning

confidence: 99%

“…Recently, Yamamoto et al demonstrated that CGI-Change (CGI-C; same as CGI-I) scores were significantly and positively associated with changes in positive syndrome scale scores, negative syndrome scale scores, and general pathological syndrome scale scores. 5 The 26 patients were 35.2 Ϯ 16.0 years old (male, 13; female, 13). Their starting dose of aripiprazole was 6.8 Ϯ 2.9 mg/day and the titrated dose was 20.4 Ϯ 9.2 mg/day.…”

Section: Methodsmentioning

confidence: 99%

Aripiprazole may be free from tachyphylaxis: Preliminary findings

Goto

Terao

Tomita

et al. 2012

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Loss of antipsychotic efficacy (tachyphylaxis), possibly linked to an increase in D2 receptor number and sensitivity, is a significant impediment to treatment in chronic schizophrenia patients. Animal studies, however, suggest that aripiprazole may be free from tachyphylaxis. The aim of the present study was to investigate this hypothesis. In this preliminary study, aripiprazole-treated patients were retrospectively investigated for the presence or absence of tachyphylaxis. Clinical Global ImpressionImprovement (CGI-I) scores did not significantly change and there was no significant association of CGI scores with fixed dose duration. This suggests that aripiprazole may be free from tachyphylaxis.Key words: antipsychotic drugs, aripiprazole, schizophrenia, tachyphylaxis.A NTIPSYCHOTIC DRUGS OFTEN lose efficacy in chronic schizophrenia patients despite continuous treatment, and this may be linked to an increase in D2 receptor number and sensitivity.1 Uchida and Mamo comprehensively reviewed the literature with respect to antipsychotic dosing and highlighted the possibility of tachyphylaxis caused by the action of antipsychotic drugs on the dopamine system. 2More recently, Tadokoro et al. demonstrated that chronic treatment with haloperidol led to significant increases in locomotor response and D2 receptor density, compared with chronic treatment of either vehicle or aripiprazole, and that there were no significant differences between vehicle and aripiprazole. Although their study was performed on animals, if extrapolated to schizophrenia patients, hypothetically, there is a possibility that aripiprazole may be free from tachyphylaxis (i.e. aripiprazole may not entail loss of efficacy despite long-term treatment).In the clinical setting, Pigott et al. showed that the mean Clinical Global Impression-Improvement Scale (CGI-I) scores at week 6 and at week 26 for 148 aripiprazole-treated patients with chronic schizophrenia were 3.67 and 3.74, suggesting that there was no tachyphylaxis in the study period.4 These findings support the hypothesis, but the treatment duration seems to be insufficient to substantiate this hypothesis.In the present preliminary study, aripiprazoletreated patients were retrospectively investigated for the presence or absence of tachyphylaxis. METHODS SubjectsFifty-one patients (14 patients from Oita University and 37 patients from Kurume University) with schizophrenia according to DSM-IV-TR and who received only aripiprazole treatment were identified for the study. Of these, 26 patients (14 patients from Oita University and 12 patients from Kurume University) were deemed eligible for inclusion because they had continued to receive aripiprazole for Ն4 weeks. The ethics committees of Oita University ProcedureClinical improvement was assessed using CGI-I when titration of aripiprazole dose was completed, compared with the basal state (at the time of starting aripiprazole). The CGI scale is a 7-point scale requiring the clinician to assess how much the patient's illness has improved or worsened; i...

show abstract

“…The preliminary questionnaire developed in the current study can be related to PANSS and hence enhance its practicality. Andreasen et al extracted 8 of the 30 items from the full PANSS in order to define remission from schizophrenia [25], in which delusion (P1) and passive/apathetic social withdrawal (N4) are overlapped with the studies conducted by Yamamoto et al selected for their brief PANSS [24]. Consistent with these previous studies, P1 and N4 were also finally selected in the current study after an integrated correlation test.…”

mentioning

confidence: 92%

“…The validation of the questionnaire, which consists of 7 questions for rating N4 and P1 selected from the 8 effective remission items of the full PANSS, showed a high correlation between the doctors and family members at 0.952 and 0.927 for males and females respectively [24]. Considering that family members will complete the questions in a short period after a brief training session (time range: 10-30 min), it is believed that the requirements of this questionnaire have been satisfied in that it can be easily used by family members and reflects the clinical features of schizophrenia to a certain extent.…”

mentioning

confidence: 99%

Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia

et al. 2016

Pharmacopsychiatry

View full text Add to dashboard Cite

show abstract

Brief PANSS to assess and monitor the overall severity of schizophrenia

Cited by 9 publications

References 6 publications

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication

Aripiprazole may be free from tachyphylaxis: Preliminary findings

Brief Questionnaire Derived from PANSS Using a General Probability Model to Assess and Monitor the Clinical Features of Schizophrenia

Contact Info

Product

Resources

About